EUVIMEDEUVIMED entdecken
Open Access

Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer

Kenji Morimoto, Tadaaki Yamada, Ryo Sawada, Koichi Azuma, Yasuhiro Goto, Taishi Harada, Shinsuke Shiotsu, Nobuyo Tamiya, Yusuke Chihara, Takayuki Takeda, Osamu Hiranuma, Isao Hasegawa und 6 weitere

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03370-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Kenji Morimoto und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajii-Cho, Kamigyo-Ku, Kyoto, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Current evidence indicates that immune checkpoint inhibitors (ICIs) have a limited efficacy in patients with lung cancer harboring epidermal growth factor receptor (EGFR) mutations. However, there is a lack of data on the efficacy of ICIs after osimertinib treatment, and the predictors of ICI efficacy are unclear. METHODS: We retrospectively assessed consecutive patients with EGFR-mutant NSCLC who received ICI-based therapy after osimertinib treatment at 10 institutions in Japan, between March 2016 and March 2021. Immunohistochemical staining was used to evaluate the expression of p53 and AXL. The deletions of exon 19 and the exon 21 L858R point mutation in EGFR were defined as common mutations; other mutations were defined as uncommon mutations. RESULTS: A total of 36 patients with advanced or recurrent EGFR-mutant NSCLC were analyzed. In multivariate analysis, p53 expression in tumors was an independent predictor of PFS after ICI-based therapy (p = 0.002). In patients with common EGFR mutations, high AXL expression was a predictor of shorter PFS and overall survival after ICI-based therapy (log-rank test; p = 0.04 and p = 0.02, respectively). CONCLUSION: The levels of p53 in pretreatment tumors may be a predictor of ICI-based therapy outcomes in patients with EGFR-mutant NSCLC after osimertinib treatment. High levels of AXL in tumors may also be a predictor of ICI-based therapy outcomes, specifically for patients with common EGFR mutations. Further prospective large-scale investigations on the predictors of ICI efficacy following osimertinib treatment are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansEpidermal Growth FactorErbB ReceptorsImmune Checkpoint InhibitorsMutationNeoplasm Recurrence, LocalProtein Kinase InhibitorsRetrospective StudiesTumor Suppressor Protein p53AcrylamidesAniline CompoundsIndolesPyrimidinesAxl Receptor Tyrosine Kinase

Stichwörter der Autor:innen

AXLEGFR mutationImmune checkpoint inhibitorNon-small cell lung cancerp53

Substanzen

Epidermal Growth FactorErbB ReceptorsImmune Checkpoint InhibitorsProtein Kinase InhibitorsTumor Suppressor Protein p53osimertinibAcrylamidesAniline CompoundsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajii-Cho, Kamigyo-Ku, Kyoto, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajii-Cho, Kamigyo-Ku, Kyoto, Japan. tayamada@koto.kpu-m.ac.jp.
  • Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka City, Japan.
  • Department of Respiratory Medicine, Fujita Health University School of Medicine, Aichi, Japan.
  • Department of Medical Oncology, Fukuchiyama City Hospital, Kyoto, Japan.
  • Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.

Zitieren

APA

Morimoto, K., Yamada, T., Sawada, R., Azuma, K., Goto, Y., Harada, T., Shiotsu, S., Tamiya, N., Chihara, Y., Takeda, T., Hiranuma, O., Hasegawa, I., Tanaka, S., Yoshimura, A., Iwasaku, M., Tokuda, S., Kim, Y. H., & Takayama, K. (2023). Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03370-1

Vancouver

Morimoto K, Yamada T, Sawada R, Azuma K, Goto Y, Harada T, et al. Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03370-1

BibTeX
@article{Morimoto2023,
  author = {Morimoto, Kenji and Yamada, Tadaaki and Sawada, Ryo and Azuma, Koichi and Goto, Yasuhiro and Harada, Taishi and Shiotsu, Shinsuke and Tamiya, Nobuyo and Chihara, Yusuke and Takeda, Takayuki and Hiranuma, Osamu and Hasegawa, Isao and Tanaka, Satomi and Yoshimura, Akihiro and Iwasaku, Masahiro and Tokuda, Shinsaku and Kim, Young Hak and Takayama, Koichi},
  title = {Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03370-1}
}
Kostenlos starten →